Reduced Muscle Loss in Patients With NSCLC Taking Fibrates: Findings From a Retrospective Observational Study

Area of Science:

• Oncology
• Metabolism
• Pharmacology

Background:

• Cancer-anorexia-cachexia syndrome (CACS) is a severe wasting disorder linked to poor outcomes.
• PPAR-α (peroxisome proliferator-activated receptor alpha) plays a role in ketone production and muscle preservation.
• Fibrates, PPAR-α agonists used for dyslipidemia, showed muscle-sparing effects in preclinical models.

Purpose of the Study:

• To investigate if PPAR-α agonists (fibrates) reduce CACS in cancer patients.
• To evaluate the impact of fibrates on skeletal muscle mass and survival in non-small cell lung cancer (NSCLC) patients.

Main Methods:

• Retrospective cohort study of 6922 NSCLC patients diagnosed between 2002-2017.
• Compared patients incidentally prescribed fenofibrate or gemfibrozil with propensity score-matched controls.
• Assessed composite CACS outcome, skeletal muscle area changes via CT imaging, and overall survival.

Main Results:

• No significant difference in the overall CACS prevalence between fibrate users and controls (49.7% vs. 46.6%).
• Patients on fibrates experienced significantly less skeletal muscle area loss over time (-3.3% vs. -4.2%, p=0.03).
• No significant difference in overall survival was observed between the groups.

Conclusions:

• Fibrate use in NSCLC patients was associated with preserved skeletal muscle mass over time.
• The observed muscle-sparing effect did not translate to improved overall survival in this study.
• Further research is needed to confirm these findings and explore potential survival benefits, as the study may have been underpowered.